Voyager Therapeutics is a clinical-stage gene-therapy company focused on neurological diseases, and its stock is covered by a mix of Wall Street firms. For this analysis, nine current, attributable price targets were reviewed: H.C. Wainwright ($25, reiterated October 2026), Guggenheim ($22), Oppenheimer ($18), Canaccord Genuity ($12), Robert W. Baird ($12), Citi ($11), Leerink Partners ($11), Wells Fargo ($10), and Wedbush ($8).
These figures produce a low-to-high range of $8 to $25 and a calculated arithmetic mean of approximately $14.33, which rounds to the central target of $14 used here. The wide spread reflects genuine disagreement about how much the pipeline is worth: higher targets embed substantial credit for the tau program's Alzheimer's optionality, while lower targets discount the risk that early-stage data or capital needs disappoint.
Aggregators generally report a similar picture. S&P Global data points to an average target near $14.2–$14.9 across roughly 11 analysts, while TipRanks' three-month window clusters around $15. None of these figures should be read as a guarantee; the mean is simply the midpoint of published expectations.
After a sharp drawdown, VYGR recently traded around $1.99, near the bottom of its 52-week range of $1.68 to $5.48. Reaching $14 from that level implies an upside of roughly 600%, an extraordinarily large move that would require a fundamental re-rating rather than a modest recovery.
The path would likely depend on clinical and partnership catalysts. Voyager's tau program and its NeuroShuttle adeno-associated virus (AAV) platform are the core of the bull case, because positive data or a large collaboration could materially expand the company's valuation. The stock is a micro-cap with a market value of roughly $115–$125 million, so even modest positive news can move the share price significantly in percentage terms.
The company held total cash of roughly $107 million as of its most recent quarter, providing runway to advance its pipeline. Analysts who maintain Buy ratings generally point to the tau program in Alzheimer's disease and to the NeuroShuttle platform's potential to deliver gene therapies across the blood-brain barrier, an area with meaningful unmet need.
Positive clinical data, a licensing or collaboration agreement, or a partner milestone payment could all support a re-rating. Because the stock has fallen so far, any credible de-risking event has the potential to produce outsized percentage gains relative to the current price.
The principal obstacle is execution risk inherent to clinical-stage biotechnology. Voyager is not profitable, posting negative EPS (earnings per share) and roughly $25 million in trailing revenue, and its value rests heavily on programs that are still early-stage and not yet proven.
The stock's decline from $5.48 to near $1.68 illustrates how quickly sentiment can deteriorate on setbacks, dilution, or disappointing data. Further capital raises, trial delays, competitive advances in Alzheimer's or gene therapy, and sector-wide risk-off conditions could all keep the shares well below analyst price targets.
The $1.68 level, hit in late October 2026, marks the 52-week low and serves as a key support level. A sustained break below it would signal further downside, while a recovery would first need to reclaim the prior consolidation zone in the low-$2 range.
The $5.48 52-week high is a distant resistance level that the stock has not approached in months. Given the roughly 600% gap between the current price and the $14 target, conventional technical milestones are of limited relevance; the thesis is fundamentally binary and catalyst-driven rather than trend-driven.
Analyst price targets typically reflect a research horizon of approximately 12 months, though individual firms may apply different timeframes or discount rates. For Voyager, the relevant horizon is shaped more by clinical timelines than by a fixed calendar window.
Investors should monitor tau program data readouts, any NeuroShuttle partnership or licensing announcements, quarterly cash burn and runway guidance, and analyst target revisions. Regulatory and financing decisions, including any equity raise, would also materially affect the path toward the target.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, track positions, and identify changing trends more efficiently than manual screening alone. For a volatile, catalyst-driven name like VYGR, automated signal monitoring can complement fundamental research by flagging momentum shifts as they emerge. Traders interested in a systematic, data-driven approach can explore the AI Daily Buy/Sell Signals to see how the tool evaluates this and other tickers.
Can VYGR reach $14? The question frames an enormous gap between a sub-$2 stock and an average analyst price target of roughly $14, implying upside of around 600%. The target is a statistical midpoint of bullish Street estimates, not a forecast, and it rests on the tau program and NeuroShuttle platform delivering value that has yet to be proven.
The supports are real—cash runway, an Alzheimer's pipeline, and a differentiated AAV platform—but the obstacles are equally real, including negative earnings, early-stage risk, and a share price already down sharply from its peak. The wide $8-to-$25 analyst range underscores genuine uncertainty. Investors should watch clinical catalysts, financing, and analyst revisions rather than treat any single number as inevitable.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VYGR has been loosely correlated with EDIT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if VYGR jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To VYGR | 1D Price Change % | ||
|---|---|---|---|---|
| VYGR | 100% | -3.56% | ||
| EDIT - VYGR | 60% Loosely correlated | -4.99% | ||
| RCKT - VYGR | 55% Loosely correlated | +1.22% | ||
| DYN - VYGR | 53% Loosely correlated | +0.39% | ||
| MGTX - VYGR | 50% Loosely correlated | +0.62% | ||
| SLDB - VYGR | 50% Loosely correlated | +6.00% | ||
More | ||||